Neuroimaging features of FOXR2‐activated CNS neuroblastoma: A case series and systematic review

BACKGROUND AND PURPOSE CNS neuroblastoma, FOXR2-activated (CNS NB-FOXR2) is a newly recognized tumor type in the 2021 World Health Organization classification of central nervous system (CNS) tumors. We aimed to investigate the clinical and neuroimaging findings of CNS NB-FOXR2 and systematically review previous publications and three new cases. METHODS We searched PubMed, SCOPUS, and Embase databases for patients with pathologically proven CNS NB-FOXR2 with sufficient information for preoperative CT and MRI findings. Two board-certified radiologists reviewed the studies and imaging data. RESULTS Thirty-one patients from six previous publications and 3 patients from our hospital comprised the study population (median age, 4.2 [range: 1.4-16] years; 19 girls). Clinically, CNS NB-FOXR2 mainly affected children between 2 and 6 years (24/34, 67.6%). Nausea/vomiting and seizures were reported as the main presenting symptoms (100% in total). The tumors frequently showed hyperdensity compared to the cortex on nonenhanced CT (4/5, 80%) with calcification along the inner rim of the tumor (4/5, 80%). More than half of patients showed susceptibility artifacts indicating intratumoral hemorrhage and/or calcification (15/28, 53.6%) on T2*- and/or susceptibility-weighted imaging. Elevated relative cerebral blood volume and flow and percentile signal recovery were observed in one case with dynamic susceptibility contrast MRI. CONCLUSIONS Characteristic imaging features including hyperdense attenuation of the solid components and calcification along the inner rim on CT and susceptibility-weighted imaging may assist with preoperative diagnosis of CNS NB-FOXR2 in pediatric patients.

[1]  M. Kool,et al.  Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions. , 2022, European journal of medical genetics.

[2]  M. Kool,et al.  Imaging Characteristics of CNS Neuroblastoma-FOXR2: A Retrospective and Multi-Institutional Description of 25 Cases , 2022, American Journal of Neuroradiology.

[3]  T. Merchant,et al.  Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children’s Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials , 2022, Acta Neuropathologica.

[4]  S. Camelo-Piragua,et al.  Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors. , 2022, Radiographics : a review publication of the Radiological Society of North America, Inc.

[5]  A. Srinivasan,et al.  Comprehensive radiological features of laryngeal sarcoidosis: cases series and systematic review , 2022, Neuroradiology.

[6]  A. Srinivasan,et al.  Neuroimaging features of angiocentric glioma: A case series and systematic review , 2022, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[7]  A. Srinivasan,et al.  Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma , 2022, European Radiology.

[8]  Remy R. Lobo,et al.  Imaging features of laryngeal chondrosarcomas: A case series and systematic review , 2022, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[9]  A. Srinivasan,et al.  Neuroradiological features of the polymorphous low-grade neuroepithelial tumor of the young: five new cases with a systematic review of the literature , 2022, Neuroradiology.

[10]  T. Johnson,et al.  Neuroimaging of astroblastomas: A case series and systematic review , 2021, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[11]  A. Srinivasan,et al.  Neuroimaging features of diffuse hemispheric glioma, H3 G34‐mutant: A case series and systematic review , 2021, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[12]  H. Urbach,et al.  Freiburg Neuropathology Case Conference , 2021, Clinical Neuroradiology.

[13]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[14]  F. Westermann,et al.  FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Kool,et al.  Therapeutic implications of improved molecular diagnostics for rare CNS-embryonal tumor entities: results of an international, retrospective study. , 2021, Neuro-oncology.

[16]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[17]  Sandeep Kumar Dhanda,et al.  Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials , 2021, Clinical Cancer Research.

[18]  David T. W. Jones,et al.  Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation , 2021, Acta Neuropathologica Communications.

[19]  U. Schüller,et al.  Detailed Clinical and Histopathological Description of 8 Cases of Molecularly Defined CNS Neuroblastomas. , 2020, Journal of neuropathology and experimental neurology.

[20]  W. Grajkowska,et al.  Molecular identification of CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1 and CNS HGNET-BCOR pediatric brain tumors using tumor-specific signature genes , 2020, Acta Neuropathologica Communications.

[21]  P. Varlet,et al.  The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts , 2020, Acta Neuropathologica Communications.

[22]  K. Ohshima,et al.  Central nervous system neuroblastic tumor with FOXR2 activation presenting both neuronal and glial differentiation: a case report , 2020, Brain Tumor Pathology.

[23]  C. Sommer,et al.  Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Boxerman,et al.  Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma , 2019, American Journal of Neuroradiology.

[25]  Yutaka Suzuki,et al.  Foxr2 promotes formation of CNS-embryonal tumors in a Trp53-deficient background. , 2019, Neuro-oncology.

[26]  P. Varlet,et al.  Imaging features of medulloblastoma: Conventional imaging, diffusion-weighted imaging, perfusion-weighted imaging, and spectroscopy: From general features to subtypes and characteristics. , 2018, Neuro-Chirurgie.

[27]  L. Massimi,et al.  Central nervous system (CNS) neuroblastoma. A case-based update , 2018, Child's Nervous System.

[28]  M. Murad,et al.  Methodological quality and synthesis of case series and case reports , 2018, BMJ Evidence-Based Medicine.

[29]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[30]  Wei Li,et al.  Susceptibility‐weighted imaging and quantitative susceptibility mapping in the brain , 2015, Journal of magnetic resonance imaging : JMRI.

[31]  S Ekholm,et al.  Percentage Signal Recovery Derived from MR Dynamic Susceptibility Contrast Imaging Is Useful to Differentiate Common Enhancing Malignant Lesions of the Brain , 2011, American Journal of Neuroradiology.

[32]  D. Yousem,et al.  Imaging findings of CNS atypical teratoid/rhabdoid tumors. , 2004, AJNR. American journal of neuroradiology.